Human Immunodeficiency Virus-1, Negative Factor
recombinant, E. coli
For in vitro use only!
Shipping: shipped on dry ice
Storage Conditions: store at -80 °C
avoid freeze/thaw cycles
Shelf Life: 12 months
Purity: > 95 % (SDS-PAGE)
Form: liquid (Supplied in 20 mM Tris-HCl pH 8.0, 100 mM NaCl and 1mM DTT)
Recombinant myristoylated signalling-defective mutant HIV-1 Nef protein (myr2-210, C210S, PxxPxP to AxxAxA) with a C-terminal His6-tag. Human immunodeficiency virus type 1 (HIV-1) Nef is a membrane-associated protein that is produced at an early stage of viral gene expression and is a component of viral particles. Nef has been demonstrated to bind and downregulate cell-surface receptors CD4, MHC class I and II molecules and DCSIGN. A Nef mutant with simple alanine substitutions at the myristoylation and dileucine sites was impaired in its ability to elicit Nef-specific CD4(+) and CD8(+) T cell responses. In addition, Nef has been reported to have diverse effects on cellular signal transduction pathways. It interacts with various cellular protein kinases and acts both as a kinase substrate and as a modulator of kinase activity.
Geyer et al. (2001) Structure-function relationships in HIV-1 Nef. EMBO reports 2:580.
Geyer et al. (2001) Domain assembly, surface accessibility and sequence conservation in full length HIV-1 Nef. FEBS Lett. 496:91.
Fackler et al. (2002) Live and let die: Nef functions beyond HIV replication. Immunity 16:493.
Peterlin et al. (2003) Hide, shield and strike back: how HIV-infected cells avoid immune eradication. Nature Immun. 3:97.
Doms et al. (2000) The plasma membrane as a combat zone in the HIV battlefield. Genes Dev. 14:2677.
Liang et al. (2002) Development of HIV-1 Nef vaccine components: immunogenicity study of Nef mutants lacking myristoylation and dileucine motif in mice. Vaccine 20:3413.